Full Press Release Details
AzurRx BioPharma to Present at Upcoming Investor
December 04, 2018 08:00 ET | Source: AzurRx BioPharma, Inc.
BROOKLYN, N.Y., Dec. 04, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma,
( AzurRx or the Company ), a company
specializing in the development of non-systemic, recombinant
therapies for gastrointestinal diseases, announced today the
Company will be making a company presentation at two upcoming
investor conferences: the LD Micro Main
Event conference in Los
Angeles at the Luxe Sunset Boulevard
Hotel, on Thursday, December
8:00 a.m. PST and at the Biotech Showcase 2019
Francisco at the Hilton San Francisco Union Square (Ballroom Level)
Thijs Spoor, President and CEO, of AzurRx will provide an overview
of the Company's business during the live presentation and will be
available to participate in one-on-one meetings with investors who
are registered to attend the conferences.
About AzurRx BioPharma, Inc.:
AzurRx BioPharma, Inc. (NASDAQ:AZRX)
is engaged in the research and development of non-systemic
biologics for the treatment of patients with gastrointestinal
disorders. MS1819 recombinant lipase for exocrine pancreatic
insufficiency is the Company's lead development program, and
additional early stage research is being conducted for the
prevention of hospital-acquired infections. The Company is
headquartered in Brooklyn, NY, with scientific operations based in
Langlade, France. Additional information on the company can be
found at www.azurrx.com.
Forward-Looking Statements:
This press release contains forward-looking statements within the
meaning of the Private Securities Litigations Reform Act of 1995.
Such statements include, but are not limited to, any statements
relating to our product development programs and any other
statements that are not historical facts. Such statements involve
risks and uncertainties that could negatively affect our business,
operating results, financial condition and stock price. Factors
that could cause actual results to differ materially from
management's current expectations include those risks and
uncertainties relating to the development and testing of our drug
candidates, the regulatory approval process, our ability to secure
additional financing, the protection of our patent and intellectual
property, the success of strategic agreements and relationships,
and the potential commercialization of any product we may
successfully develop. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in our expectations or any changes in events, conditions or
circumstances on which any such statement is based, except as
AzurRx BioPharma, Inc.
760 Parkside Avenue, Suite 304